Summary of Safety and Clinical Performance MDR Services

Under EU MDR, Class IIa, IIb, and III devices are medium- to high-risk medical devices classified by intended purpose and risk profile. Class IIa generally covers lower-medium risk devices, Class IIb includes higher-risk active or long-term use devices, and Class III covers the highest-risk products such as many implantables. Classification affects conformity assessment, clinical evidence depth, and whether an SSCP is required.

EU MDR applies to general medical devices, while IVDR applies specifically to in vitro diagnostic devices such as assays, reagents, and diagnostic instruments. Although both regulations increase scrutiny around evidence, documentation, and post-market obligations, IVDR uses performance evaluation concepts tailored to diagnostics, whereas MDR focuses on clinical evaluation and device safety and performance in patient use.

SSCP stands for Summary of Safety and Clinical Performance. Under EU MDR, it is required for Class III devices and implantable devices, with limited exceptions. The document is intended to present key information about the device's safety, clinical performance, intended purpose, residual risks, and clinical evidence in a clear format for users and patients, while remaining consistent with the technical documentation.

An SSCP is generally required for Class III devices and implantable devices under EU MDR, except for certain well-defined exemptions. Whether your device qualifies depends on its classification, intended purpose, and regulatory status. The SSCP must be validated through the conformity assessment process and kept aligned with the current clinical evaluation, risk management, and post-market surveillance documentation throughout the device lifecycle.

An SSCP typically includes device identification details, intended purpose, indications, target populations, contraindications, residual risks, undesirable effects, summary of clinical evaluation, and relevant post-market follow-up information. It should also reflect benefit-risk conclusions and be consistent with labeling, CER content, PMCF outputs, and technical documentation. Accuracy, traceability, and readability are all essential for a defensible SSCP.

The SSCP is not a replacement for the Clinical Evaluation Report; it is a public-facing summary derived from the broader clinical and regulatory evidence base. The CER contains the detailed methodology, literature appraisal, data analysis, and clinical conclusions, while the SSCP presents key safety and performance information in a concise format. Any inconsistency between the two can create review issues during conformity assessment.

A draft SSCP can be started early, but it should not be finalized in isolation from the technical documentation. Because the SSCP depends on stable inputs from the CER, risk management file, PMCF documentation, labeling, and device description, preparing it too early often leads to inconsistencies and rework. The strongest approach is to develop it alongside the final stages of evidence and documentation alignment.

The SSCP should be reviewed and updated whenever relevant information changes, especially after updates to clinical evaluation, PMCF findings, risk management conclusions, labeling, or post-market surveillance outputs. It is not a one-time deliverable. Manufacturers should treat it as a controlled regulatory document that evolves with the device's evidence base and remains consistent with the current approved technical documentation.